Changes in Beneficial Ownership · 4
Pharvaris N.V.
PHVSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-21
- Issuer
- Pharvaris N.V.
- Issuer CIK
- 0001830487
- Trading symbol
- PHVS
Reporting owner 1
- Name
- Nassif David W.
- Reporting owner CIK
- 0001636975
- Relationship
- Officer
- Officer title
- CFO / CLO
- Address
- 1 CRANBERRY HILL SUITE 400, LEXINGTON, LEXINGTON, MA, 02421
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-21 | S · Form 4 | 6,000 | D | 36.4668[F1] | 114,300 | D |
| Common Stock | 2026-09-21 | G · Form 4[F2] | 500 | D | 0 | 113,800 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
- G · Form 4
- Bona fide gift
Footnotes
- F1
- The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $36.30 to $36.71 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.↩ 1
- F2
- Gift to charitable organization.↩ 1
Signature 1
- Signed
- /s/ Marnus Nel, Attorney-in-Fact for David W. Nassif
- Date
- 2026-09-23
Company context
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by VIKING GLOBAL INVESTORS LP regarding Pharvaris N.V.Nov 16, 2026
- SCHEDULE 13G - filed by WELLINGTON MANAGEMENT GROUP LLP regarding Pharvaris N.V.Nov 16, 2026
- SCHEDULE 13G/A - filed by GENERAL ATLANTIC, L.P. regarding Pharvaris N.V.Nov 13, 2026
- 6-K filingNov 12, 2026
- 144 filingSep 23, 2026